Cancer immunotherapy based on immune checkpoint blockade has provided significant clinical benefits in many cancers. Despite the encouraging and promising clinical responses observed in a few patients, the majority have only a short-term survival benefit, if any, and severe side effects.
There is a clinical urge to design combinatorial strategies to extend the benefits of immunotherapy to a large number of cancer patients.
The Luxembourg Institute of Health partnered with French Biotech company Advanced BioDesign to develop novel approaches that effectively extend the benefit of cancer immunotherapy. This collaboration aims to potentiate the effectiveness of immunotherapy and provide a revolutionary approach to treating cancers.
Combing innovative and highly selective molecules inhibiting resistance mechanisms in multiple cancers
This collaboration is bringing about ” TRICK-ALDH “. In this project, scientists will evaluate the benefits of immunotherapy combined with premium oncology drugs to effectively suppress carcinogenesis and prevent resistance to cancer therapies.
The overall objective of the TRICK-ALDH project is to provide a new, rational combination of targeted therapy and immunotherapy to achieve long-term survival benefit for solid tumours, with a particular focus on melanoma and lung cancer.
As a result of this collaboration between Research Luxembourg’s scientists and Advanced BioDesign, the teams hope to develop innovative immunotherapeutic combination approaches that could generate considerable momentum in the field of cancer care.
Making the most of the scientific and business expertise
Building bridges between science and the industry is a priority for Luxembourg. The TRICK-ALDH project is a prime example of this commitment to stimulate partnerships between public research institutes and companies as it received financial support from the Luxembourg National Research Fund under the BRIDGES scheme. This programme aims to provide financial support for industry partnerships between public research institutions in Luxembourg and national or international companies.
“We believe that true translational oncology and translational research in general can only effectively be achieved by leveraging the scientific and business expertise of internationally renowned industrial partners. We are confident that our close collaboration with Advanced BioDesign will catalyse the development of the next-generation of combinatorial treatments for a variety of cancers, with concrete and tangible benefits in the clinical practice.”Dr Bassam Janji, Head of Tumor Immunotherapy and Microenvironment group, Luxembourg Institute of Health
More about this partnership.
What’s the digital status of global economies in post-pandemic times? According to the 2021 World Digital Competitiveness Ranking, Luxembourg moved up six places to 22nd overall. The country stands out in particular for its regulatory framework, including scientific research legislation, and capital. Strong scientific research legislation Luxembourg’s good performance in the technology category is notably…Keep reading
Digital technologies are critical in sustaining economic competitiveness in the future. According to UNESCO Science Report 2021, Luxembourg is one of the five EU members featured among the top ten countries globally for publications on cross-cutting tech per million inhabitants. With 245 publications in the field of cross-cutting strategic technologies, Luxembourg’s scientific output is among…Keep reading
How much does Luxembourg government allocate for R&D? How does it compare with other EU countries? According to Eurostat, Luxembourg devoted the highest allocations in the EU with €648 per person in 2020. In comparison, government budget allocations for R&D at an EU level stood at €225 per person. Research & Development a priority for Luxembourg…Keep reading